Shanghai Fudan Forward S&T Co Ltd
SSE:600624
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (23.9), the stock would be worth ¥-3.32 (178% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -30.8 | ¥4.28 |
0%
|
| Industry Average | 23.9 | ¥-3.32 |
-178%
|
| Country Average | 28.8 | ¥-4.01 |
-194%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
S
|
Shanghai Fudan Forward S&T Co Ltd
SSE:600624
|
2.9B CNY | -30.8 | -24.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 27.4 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 16.7 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.9 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 15.6 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 12.1 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 9.5 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8.4 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 7.6 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 7.2 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.3 |
| Median | 28.8 |
| 70th Percentile | 53.1 |
| Max | 49 021 |
Other Multiples
Shanghai Fudan Forward S&T Co Ltd
Glance View
Shanghai Fudan Forward S&T Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 1,532 full-time employees. The firm's pharmaceuticals include digestive system drugs, nervous system drugs, antineoplastic drugs, circulatory drugs, immune function medications and others. The firm is also engaged in the provision of financial insurance software products. The company distributes its products within domestic markets and to overseas markets.
